Program
alimatravir
Also written as “MK-8527”, “Alimatravir” and “[14C]MK-8527”.
Its studies are mostly in Acquired Immunodeficiency Syndrome · Renal Insufficiency, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 174 open or running | phase 3since Jun 26, 2025 | Jul 30, 2018 | Jan 19, 2027phase 1 · NCT07600775 |
- Named in Merck’s own pipeline as
alimatravir MK-8527
, phase 3, as of Nov 2, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Jul 30, 2018.
- Sep 13, 2023Phase 2 study in HIVNCT06045507 · 352 enrolled · United States, Israel, South Africa
- Feb 29, 2024Phase 1 study in Renal InsufficiencyNCT06295796 · 18 enrolled · United States
- Aug 28, 2024Phase 1 study in HealthyNCT06580587 · 13 enrolled · United States
- Jan 14, 2025Phase 1 study in Acquired Immunodeficiency SyndromeNCT06783192 · 14 enrolled · United States
- Feb 4, 20252 phase 1 studies in HealthyNCT06816043, NCT06826989
- Mar 18, 2025Phase 1 study in HealthyNCT06893081 · 16 enrolled · United States
- Jun 9, 2025Phase 1 study in Hepatic ImpairmentNCT07025551 · 18 enrolled · United States
- Jun 26, 2025Phase 3 study in Acquired Immunodeficiency SyndromeNCT07044297 · 4,390 enrolled · United States, Argentina, Brazil and more
- Jul 3, 2025Phase 1 study in HealthyNCT07063238 · 42 enrolled · United States
- Jul 8, 2025Phase 3 study in Acquired Immunodeficiency SyndromeNCT07071623 · 4,580 planned · Kenya, South Africa, Uganda
- Apr 7, 2026Phase 1 study in HealthyNCT07528508 · 14 enrolled · United States
- May 15, 2026Phase 1 study in Acquired Immunodeficiency SyndromeNCT07600775 · 14 planned
- Jun 16, 2026Phase 1 study in HealthyNCT07661108 · 44 enrolled · United States
- Sep 23, 2026Phase 2 study in HIVNCT07850609 · 80 planned · United States, Canada
Ahead
- Jan 19, 2027Primary completion: phase 1 study in Acquired Immunodeficiency SyndromeNCT07600775
- Jul 22, 2027Primary completion: phase 3 study in Acquired Immunodeficiency SyndromeNCT07044297
- Oct 18, 2027Primary completion: phase 3 study in Acquired Immunodeficiency SyndromeNCT07071623
- Dec 2, 2027Primary completion: phase 2 study in HIVNCT07850609
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07850609HIV · United States, Canada | 2 | Recruiting | Dec 2, 2027 | 80 |
| NCT07661108Healthy · United States | 1 | Completed | Oct 28, 2026 | 44 |
| NCT07600775Acquired Immunodeficiency Syndrome | 1 | Not yet recruiting | Jan 19, 2027 | 14 |
| NCT07528508Healthy · United States | 1 | Completed | Jul 31, 2026 | 14 |
| NCT07071623Acquired Immunodeficiency Syndrome · Kenya, South Africa, Uganda | 3 | Recruiting | Oct 18, 2027 | 4,580 |
| NCT07063238Healthy · United States | 1 | Completed | Dec 6, 2025 | 42 |
| NCT07044297Acquired Immunodeficiency Syndrome · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Jul 22, 2027 | 4,390 |
| NCT07025551Hepatic Impairment · United States | 1 | Completed | Feb 13, 2026 | 18 |
| NCT06893081Healthy · United States | 1 | Completed | Jun 19, 2025 | 16 |
| NCT06826989Healthy · United States | 1 | Completed | Jun 4, 2025 | 8 |
| NCT06816043Healthy · United States | 1 | Completed | Jun 5, 2025 | 20 |
| NCT06783192Acquired Immunodeficiency Syndrome · United States | 1 | Completed | Oct 11, 2023 | 14 |
| NCT06580587Healthy · United States | 1 | Completed | Mar 27, 2026 | 13 |
| NCT06295796Renal Insufficiency · United States | 1 | Completed | Jan 31, 2025 | 18 |
| NCT06045507HIV · United States, Israel, South Africa | 2 | Completed | Dec 12, 2024 | 352 |
| NCT05494736Acquired Immunodeficiency Syndrome · Romania, South Africa | 1 | Completed | Jan 31, 2024 | 20 |
| NCT03615183Acquired Immunodeficiency Syndrome · Romania | 1 | Completed | Sep 26, 2019 | 17 |
How it is read
Names in the registry
- “MK-8527”, 15 entries
- “Alimatravir”, 1 entry
- “[14C]MK-8527”, 1 entry
Conditions, from the studies’ own filings
- Acquired Immunodeficiency Syndrome, 6 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.